Kite, a Gilead Company and Appia Bio Announce Collaboration

Gilead Sciences Inc. said its Kite unit signed a collaboration and license agreement with biotechnology startup Appia Bio Inc. to research and develop allogeneic cell therapies for cancer. The technology is based on the work of UCLA Researcher and Professor, Lili Yang PhD. Click here to read more.